Editas Medicine is a biotechnology company that focuses on developing transformative therapies based on the groundbreaking gene editing technology known as CRISPR
The company is dedicated to harnessing the power of this technology to correct genetic defects, treat serious diseases, and ultimately improve patient outcomes. Editas is engaged in advancing research and development initiatives aimed at addressing various genetic disorders, including inherited diseases and conditions that currently lack effective treatments, all while driving innovation in the field of genomic medicine. Through collaboration with leading scientists and institutions, Editas aims to bring its pioneering therapies from the lab to the clinic, making a meaningful impact in the lives of patients.
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing.
